TWI704917B - 治療嚴重便祕的組合物及方法 - Google Patents

治療嚴重便祕的組合物及方法 Download PDF

Info

Publication number
TWI704917B
TWI704917B TW108109164A TW108109164A TWI704917B TW I704917 B TWI704917 B TW I704917B TW 108109164 A TW108109164 A TW 108109164A TW 108109164 A TW108109164 A TW 108109164A TW I704917 B TWI704917 B TW I704917B
Authority
TW
Taiwan
Prior art keywords
dgat1
inhibitor
constipation
individual
pharmaceutically acceptable
Prior art date
Application number
TW108109164A
Other languages
English (en)
Chinese (zh)
Other versions
TW201944995A (zh
Inventor
布萊恩 Ｋ 哈伯德
吳 麥可 Ｈ 瑟藍諾
Original Assignee
開曼群島商安濟藥業有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 開曼群島商安濟藥業有限公司 filed Critical 開曼群島商安濟藥業有限公司
Publication of TW201944995A publication Critical patent/TW201944995A/zh
Application granted granted Critical
Publication of TWI704917B publication Critical patent/TWI704917B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW108109164A 2018-03-16 2019-03-18 治療嚴重便祕的組合物及方法 TWI704917B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862644033P 2018-03-16 2018-03-16
US62/644,033 2018-03-16

Publications (2)

Publication Number Publication Date
TW201944995A TW201944995A (zh) 2019-12-01
TWI704917B true TWI704917B (zh) 2020-09-21

Family

ID=67904819

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108109164A TWI704917B (zh) 2018-03-16 2019-03-18 治療嚴重便祕的組合物及方法

Country Status (18)

Country Link
US (4) US11224590B2 (https=)
EP (1) EP3765012B1 (https=)
JP (1) JP7527984B2 (https=)
KR (1) KR102747096B1 (https=)
CN (1) CN111936137B (https=)
AU (1) AU2019234956B2 (https=)
BR (1) BR112020018790A2 (https=)
DK (1) DK3765012T3 (https=)
EA (1) EA202092190A1 (https=)
FI (1) FI3765012T3 (https=)
IL (1) IL277332B2 (https=)
MX (1) MX2020009604A (https=)
MY (1) MY205335A (https=)
PE (1) PE20210158A1 (https=)
PH (1) PH12020551468A1 (https=)
SG (1) SG11202008971VA (https=)
TW (1) TWI704917B (https=)
WO (1) WO2019178492A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202092190A1 (ru) 2018-03-16 2020-11-19 Анджи Фармасьютикалз Инк. Композиции и способы для лечения сильного запора
KR20220052459A (ko) 2020-10-21 2022-04-28 주식회사 엘지에너지솔루션 전극 탭 고정부를 포함하는 용접장치 및 이를 이용한 전극 탭 용접 방법

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3225997A (en) 1996-05-30 1998-01-05 Trustees Of Columbia University In The City Of New York, The Dna encoding acylcoenzyme a: cholesterol acyltransferase and uses thereof
ATE406448T1 (de) 1998-06-24 2008-09-15 David Gladstone Inst Diacylglycerin o-acyltransferase
US20030167483A1 (en) 1998-06-24 2003-09-04 Farese Robert V. Diacylglycerol O-acyltransferase
US6344548B1 (en) 1998-06-24 2002-02-05 The Regents Of The University Of California Diacylglycerol o-acyltransferase
US20030154504A1 (en) 1998-06-24 2003-08-14 Farese Robert V. Methods and compositions for modulating carbohydrate metabolism
US6100077A (en) 1998-10-01 2000-08-08 The Trustees Of Columbia University In The City Of New York Isolation of a gene encoding diacylglycerol acyltransferase
WO2002002551A1 (en) 2000-06-30 2002-01-10 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
US6444427B1 (en) 2000-07-11 2002-09-03 The Regents Of The University Of California Polymorphisms in a diacylglycerol acyltransferase gene, and methods of use thereof
JP4164645B2 (ja) 2002-08-09 2008-10-15 株式会社大塚製薬工場 Ｄｇａｔ阻害剤
RU2342388C2 (ru) 2002-11-22 2008-12-27 Джапан Тобакко Инк. Конденсированные бициклические азотсодержащие гетероциклы, обладающие dgat ингибирующим действием
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
AR044152A1 (es) 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
WO2005013907A2 (en) 2003-08-07 2005-02-17 Japan Tobacco Inc. Pyrrolo[1,2-b]pyridazine derivatives
GB0325192D0 (en) 2003-10-29 2003-12-03 Astrazeneca Ab Method of use
JP2005206492A (ja) 2004-01-21 2005-08-04 Sankyo Co Ltd スルホンアミド化合物
AU2005209115A1 (en) 2004-01-30 2005-08-11 Japan Tobacco Inc. Anorectic compounds
JP2006045209A (ja) 2004-07-02 2006-02-16 Sankyo Co Ltd ウレア誘導体
WO2006004200A1 (ja) 2004-07-02 2006-01-12 Sankyo Company, Limited ウレア誘導体
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
WO2006044775A2 (en) 2004-10-15 2006-04-27 Bayer Pharmaceuticals Corporation Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
BRPI0519058A2 (pt) 2004-12-14 2008-12-23 Astrazeneca Ab composto ou um sal prà-droga farmaceuticamente aceitÁvel do mesmo, mÉtodos para produzir uma inibiÇço da atividade de dgat1 e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composiÇço farmacÊutica, e, processo para preparar um composto
WO2006113919A2 (en) 2005-04-19 2006-10-26 Bayer Pharmaceuticals Corporation Aryl alkyl acid derivatives for and use thereof
WO2007002740A2 (en) 2005-06-28 2007-01-04 E. I. Du Pont De Nemours And Company Buffer compositions
EP2418202B1 (en) * 2006-03-31 2014-01-29 Novartis AG (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivatives as DGAT inhibitors
GB0611506D0 (en) 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
JO2972B1 (en) * 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
WO2009112445A1 (en) * 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
US8324241B2 (en) 2008-04-11 2012-12-04 Bristol-Myers Squibb Company Triazolo compounds useful as DGAT1 inhibitors
NZ602125A (en) * 2010-03-30 2014-01-31 Novartis Ag Uses of dgat1 inhibitors
CN102869645A (zh) * 2010-04-08 2013-01-09 美迪诺亚公司 用于治疗肠易激综合征的方法和组合物
AR083417A1 (es) * 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
WO2013130370A2 (en) 2012-03-01 2013-09-06 Merck Sharp & Dohme Corp. Compounds as dgat-1 inhibitors
WO2013169648A1 (en) * 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
MX2015002210A (es) * 2012-08-29 2015-05-08 Salix Pharmaceuticals Inc Composiciones laxantes y metodos para tratar estreñimiento y enfermedades y condiciones gastrointestinales relacionadas.
BR112016015851A2 (pt) * 2014-01-09 2017-08-08 Sanofi Sa Formulações farmacêuticas estabilizadas de insulina aspart
EA202092190A1 (ru) 2018-03-16 2020-11-19 Анджи Фармасьютикалз Инк. Композиции и способы для лечения сильного запора

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
H. Denison, C. Nilsson, M. Kujacic, L. Löfgren, C. Karlsson, M. Knutsson, J. W. Eriksson, "Proof of mechanism for the DGAT1 inhibitor AZD7687: Results from a first-time-in-human single-dose study"Diabetes Obesity and Metabolism 15(2) , September 2012. *
Kenneth Kulmatycki et al.,"Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor", International Journal of Clinical Pharmacology and Therapeutics, Vol. 53,No. 5, 2015, page 345-355. *

Also Published As

Publication number Publication date
MY205335A (en) 2024-10-16
US20240293376A1 (en) 2024-09-05
US11224590B2 (en) 2022-01-18
US20190282549A1 (en) 2019-09-19
US20220193044A1 (en) 2022-06-23
DK3765012T3 (da) 2026-04-27
EP3765012B1 (en) 2026-03-04
BR112020018790A2 (pt) 2020-10-13
JP7527984B2 (ja) 2024-08-05
US20260000651A1 (en) 2026-01-01
KR20200136428A (ko) 2020-12-07
EP3765012A1 (en) 2021-01-20
MX2020009604A (es) 2023-01-25
CN111936137A (zh) 2020-11-13
KR102747096B1 (ko) 2024-12-26
PE20210158A1 (es) 2021-01-26
SG11202008971VA (en) 2020-10-29
EP3765012A4 (en) 2021-12-15
AU2019234956B2 (en) 2025-01-30
WO2019178492A1 (en) 2019-09-19
JP2021518431A (ja) 2021-08-02
IL277332B2 (en) 2025-01-01
IL277332B1 (en) 2024-09-01
CN111936137B (zh) 2023-09-08
EA202092190A1 (ru) 2020-11-19
IL277332A (en) 2020-10-29
US12343334B2 (en) 2025-07-01
FI3765012T3 (fi) 2026-04-17
PH12020551468A1 (en) 2021-09-01
CA3093970A1 (en) 2019-09-19
AU2019234956A1 (en) 2020-10-01
TW201944995A (zh) 2019-12-01
US11819495B2 (en) 2023-11-21

Similar Documents

Publication Publication Date Title
JP7835558B2 (ja) 動物における疼痛の処置のためのアサ抽出物
US20260000651A1 (en) Compositions and methods for treating severe constipation
EP2685992A1 (en) Amino-quinolines as kinase inhibitors
CN105769928B (zh) 丁酸梭状芽孢杆菌在防治或辅助治疗高血糖制剂中的应用
KR101755360B1 (ko) 난각막 성분을 포함한 인슐린 저항성 개선제 및 그것을 이용한 조성물
CN117695277B (zh) 苯丙酸类似物的光学异构体组合物治疗或预防代谢紊乱中的用途
CN117771238B (zh) 苯丙酸类似物在治疗或预防代谢紊乱中的用途
US9132108B2 (en) Pharmaceutical composition for ameliorating and/or preventing leptin resistance, and use thereof
CA3191276A1 (en) Ionic liquid formulations for treating diabetes
CA3093970C (en) Compositions and methods for treating severe constipation
JP2019522030A (ja) 肝性脳症の治療方法
WO2025011534A1 (zh) 用于增强运动表现的方法及组合物
WO2013005834A1 (ja) 高純度ｅｐａを含有する抗肥満剤
CA3051789A1 (fr) Principe actif pharmaceutique et utilisation en particulier dans la prevention et le traitement des dereglements metaboliques chez l'homme et l'animal
KR20130035425A (ko) Ｈｓ1792를 유효성분으로 함유하는 염증성 질환 예방 또는 치료용 조성물
JP7142014B2 (ja) グルコサミン類の生物学的利用率向上方法
EA030590B1 (ru) Применение тиазолопиримидинона для лечения воспалительного заболевания кишечника
AU2012229871B2 (en) New composition
CN120168490A (zh) 化合物及其组合物在制备治疗非酒精性脂肪肝的药物中的应用
JP2006206547A (ja) 頻尿改善剤およびそれを含む医薬組成物および食品
CN107708705A (zh) 改善肾脏病患者的肾脏功能和/或心脏功能的方法